News
05-31-2014, 03:10 AM
Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.
More... (http://www.news-medical.net/news/20140531/Angiochem-commences-ANG1005-Phase-2-clinical-study-in-HER22b-breast-cancer-patients-with-brain-metastases.aspx)
More... (http://www.news-medical.net/news/20140531/Angiochem-commences-ANG1005-Phase-2-clinical-study-in-HER22b-breast-cancer-patients-with-brain-metastases.aspx)